A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Public ClinicalTrials.gov record NCT02498613. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable), including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also block the flow of oxygen to the tumor, and may help make the tumor more sensitive to olaparib.
Study identification
- NCT ID
- NCT02498613
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 122 participants
Conditions and interventions
Conditions
- Advanced Malignant Solid Neoplasm
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Lung Small Cell Carcinoma
- Metastatic Pancreatic Adenocarcinoma
- Metastatic Triple-Negative Breast Carcinoma
- Pancreatic Ductal Adenocarcinoma
- Stage III Breast Cancer AJCC v7
- Stage III Lung Non-Small Cell Cancer AJCC v7
- Stage III Lung Small Cell Carcinoma AJCC v7
- Stage III Pancreatic Cancer AJCC v6 and v7
- Stage IIIA Breast Cancer AJCC v7
- Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Stage IIIA Lung Small Cell Carcinoma AJCC v7
- Stage IIIB Breast Cancer AJCC v7
- Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Stage IIIB Lung Small Cell Carcinoma AJCC v7
- Stage IIIC Breast Cancer AJCC v7
- Stage IV Breast Cancer AJCC v6 and v7
- Stage IV Lung Non-Small Cell Cancer AJCC v7
- Stage IV Lung Small Cell Carcinoma AJCC v7
- Stage IV Pancreatic Cancer AJCC v6 and v7
- Triple-Negative Breast Carcinoma
- Unresectable Lung Small Cell Carcinoma
- Unresectable Pancreatic Adenocarcinoma
- Unresectable Pancreatic Carcinoma
- Unresectable Triple-Negative Breast Carcinoma
Interventions
- 18F-Fluoromisonidazole Other
- Cediranib Maleate Drug
- Laboratory Biomarker Analysis Other
- Olaparib Drug
- Positron Emission Tomography Procedure
Other · Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 30, 2016
- Primary completion
- Jun 21, 2022
- Completion
- Apr 9, 2027
- Last update posted
- Jun 16, 2026
2016 – 2027
United States locations
- U.S. sites
- 14
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| University of California Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| UC San Diego Medical Center - Hillcrest | San Diego | California | 92103 | — |
| UCSF Medical Center-Mount Zion | San Francisco | California | 94115 | — |
| Smilow Cancer Center/Yale-New Haven Hospital | New Haven | Connecticut | 06510 | — |
| Yale University | New Haven | Connecticut | 06520 | — |
| Moffitt Cancer Center-International Plaza | Tampa | Florida | 33607 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Wayne State University/Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Weisberg Cancer Treatment Center | Farmington Hills | Michigan | 48334 | — |
| Vanderbilt University/Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| UT MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| VCU Massey Comprehensive Cancer Center | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02498613, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 16, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02498613 live on ClinicalTrials.gov.